| T | Act | Project | Year | Sub | Principal Investigator(s)/ Project Leader(s) | Organization | Fiscal Year | Admin IC | Funding IC | FY Total Cost by IC | Similar Projects |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder | |||||||||||
| 5Tf | UH3Actf | DA050308Projectf | 04Yearf | INDIVIOR, INC. | 2024 | NIDA | NIDA | $287,245 | View View Similar Projects Similar Projectsf | ||
| Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder | |||||||||||
| 4Tf | UH3Actf | DA050308Projectf | 03Yearf | INDIVIOR, INC. | 2023 | NIDA | NIDA | $2,378,184 | View View Similar Projects Similar Projectsf | ||
| T | Act | Project | Year | Sub | Principal Investigator(s)/ Project Leader(s) | Organization | Fiscal Year | Admin IC | Funding IC | FY Total Cost by IC | Similar Projects |
|---|